Abstract
Objective: To compare the efficacy of weekly Peg-interferon-α, weight based ribavirin and sofosbuvir daily for 12 weeks with weight
based ribavirin and sofosbuvir daily for 24 weeks in patients with genotype 3a chronic hepatitis C patients.
Study Design: Cross-sectional analytical comparative study
Place and Duration: Department of Medicine, Aziz Bhatti Shaheed Teaching Hospital Gujrat from November 2015 to July 2017
Methodology: Patients with chronic hepatitis C genotype 3 infection were divided in two equal groups. Group A included patients
treated with Peg-interferon-α weekly, weight based ribavirin and sofosbuvir daily for 12 weeks and group B included patients
treated with weight-based ribavirin and sofosbuvir daily for 24 weeks.
Results: Each group contained 107(N) patients. Mean age in group A was 42.22+10.66 years compared to 49.66+10.51 years in
group B. Early virological response (EVR) was achieved by 98.13% patients in group A compared to 97.2% in group B. End treatment
response (ETR) rates were similar in both groups as EVR rates. Sustained virological response at 24 weeks (SVR24) was achieved by
94% patients in group A compared to 90% in group B. Binary logistic regression analysis showed no association of treatment history
and presence of cirrhosis with either of EVR, ETR or SVR24 (p>0.05). Significant difference in treatment response with either regimen
was not noted.
Conclusion: Dual and triple therapy regimens are equally effective in treating chronic hepatitis C genotype 3 patients.
Zamir Butt, Syed Muhammad Ali Shah, Syed Usama Talat, Muhammad Ajmal, Irfan Younis, Muhammad Afzal. (2019) Comparison of sofosbuvir, ribavirin plus peg-interferon-α treatment with sofosbuvir plus ribavirin alone in patients with chronic Hepatitis C, Isra Medical Journal, Volume 11, issue 6.
-
Views
838 -
Downloads
94
Previous Article
